IL241917B - Formulations for subcutaneous administration of furosemide - Google Patents

Formulations for subcutaneous administration of furosemide

Info

Publication number
IL241917B
IL241917B IL241917A IL24191715A IL241917B IL 241917 B IL241917 B IL 241917B IL 241917 A IL241917 A IL 241917A IL 24191715 A IL24191715 A IL 24191715A IL 241917 B IL241917 B IL 241917B
Authority
IL
Israel
Prior art keywords
furosemide
pharmaceutical formulations
subcutaneous administration
subcutaneous
administration
Prior art date
Application number
IL241917A
Other languages
English (en)
Hebrew (he)
Inventor
A Michaels Scott
Muntendam Pieter
Larsen Glen
Original Assignee
A Michaels Scott
Muntendam Pieter
Larsen Glen
Scpharmaceuticals Inc
Sc pharmaceuticals inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Michaels Scott, Muntendam Pieter, Larsen Glen, Scpharmaceuticals Inc, Sc pharmaceuticals inc filed Critical A Michaels Scott
Publication of IL241917B publication Critical patent/IL241917B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL241917A 2013-04-05 2015-10-06 Formulations for subcutaneous administration of furosemide IL241917B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Publications (1)

Publication Number Publication Date
IL241917B true IL241917B (en) 2020-10-29

Family

ID=51659206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241917A IL241917B (en) 2013-04-05 2015-10-06 Formulations for subcutaneous administration of furosemide

Country Status (14)

Country Link
US (5) US9884039B2 (enExample)
EP (3) EP2981258B8 (enExample)
JP (2) JP6415535B2 (enExample)
KR (2) KR102266460B1 (enExample)
CN (1) CN105431145B (enExample)
AU (1) AU2014248164B2 (enExample)
CA (1) CA2908935C (enExample)
DK (1) DK2981258T3 (enExample)
ES (1) ES2823589T3 (enExample)
IL (1) IL241917B (enExample)
MX (1) MX367165B (enExample)
PT (1) PT2981258T (enExample)
SG (2) SG11201508251RA (enExample)
WO (1) WO2014165660A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431145B (zh) * 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
DE102014115951A1 (de) * 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
IL300152A (en) * 2020-08-05 2023-03-01 Scpharmaceuticals Inc Methods of treatment using furosemide
WO2022212813A1 (en) 2021-04-02 2022-10-06 Scpharmaceuticals Inc. Subcutaneous infusion of furosemide
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
ES2136090T3 (es) * 1991-05-30 1999-11-16 Abbott Lab Reactivos que contienen un inhibidor de fijacion no especifico para analisis de fijacion con captura de iones.
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
AU4866196A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
PL1803934T3 (pl) 2005-12-28 2009-03-31 Sensile Pat Ag Mikropompa
ES2780193T3 (es) * 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
MX340669B (es) * 2008-09-09 2016-07-20 Cima Labs Inc Formas farmaceuticas para compuestos debilmente ionizables.
MX2012002762A (es) * 2009-09-04 2012-06-12 Minipumps Llc Parche cutaneo adhesivo con bomba para suministro subcutaneo de farmacos.
CN103998047A (zh) 2011-10-19 2014-08-20 墨卡托医疗系统公司 局部调节组织和细胞以提高疗效包括肾去神经支配
CN105431145B (zh) 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12042709B1 (en) * 2022-02-22 2024-07-23 Craig E. Williams Fighting training device

Also Published As

Publication number Publication date
US20160051507A1 (en) 2016-02-25
US20250339397A1 (en) 2025-11-06
JP2016515623A (ja) 2016-05-30
KR20210075211A (ko) 2021-06-22
EP3799869A1 (en) 2021-04-07
MX2015014064A (es) 2017-04-13
US20230201156A1 (en) 2023-06-29
EP2981258B1 (en) 2020-08-12
EP4696308A1 (en) 2026-02-18
ES2823589T3 (es) 2021-05-07
CN105431145B (zh) 2019-12-10
KR102493735B1 (ko) 2023-01-30
US10272064B2 (en) 2019-04-30
JP6415535B2 (ja) 2018-10-31
JP6677779B2 (ja) 2020-04-08
BR112015025204A2 (pt) 2021-03-16
US20180303790A1 (en) 2018-10-25
KR102266460B1 (ko) 2021-06-17
MX367165B (es) 2019-08-07
CN105431145A (zh) 2016-03-23
CA2908935C (en) 2021-06-15
US11433044B2 (en) 2022-09-06
US12370168B2 (en) 2025-07-29
HK1221152A1 (zh) 2017-05-26
SG10201709388QA (en) 2017-12-28
US20200038364A1 (en) 2020-02-06
CA2908935A1 (en) 2014-10-09
EP2981258A1 (en) 2016-02-10
AU2014248164B2 (en) 2019-05-23
KR20160014592A (ko) 2016-02-11
EP2981258A4 (en) 2016-10-05
DK2981258T3 (da) 2020-10-19
EP3799869B1 (en) 2025-08-27
EP2981258B8 (en) 2020-11-11
AU2014248164A1 (en) 2015-10-15
PT2981258T (pt) 2020-10-19
WO2014165660A1 (en) 2014-10-09
JP2019001821A (ja) 2019-01-10
US9884039B2 (en) 2018-02-06
SG11201508251RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
EP3082817A4 (en) Compositions for drug administration
ZA201504582B (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP4005604B8 (en) Delivery of drugs
SG10201709388QA (en) Pharmaceutical formulations for subcutaneous administration of furosemide
IL240797B (en) Oral formulations of deferasirox
SG11201604706TA (en) Stabilized pharmaceutical formulations of insulin aspart
EP3038465A4 (en) Oral pharmaceutical formulation of omarigliptin
PT2968368T (pt) Administração craniana de substâncias farmacêuticas
ZA201507576B (en) Pharmaceutical combination drug
AP2015008208A0 (en) Pharmaceutical administration forms comprising
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
DK2964193T3 (da) Lægemidler til oral indgivelse
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
GB201318686D0 (en) Pharmaceutical preparations
EP2958593A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TRANSMUCOSAL ADMINISTRATION OF BENZODIAZEPINES
GB201301721D0 (en) Pharmaceutical Preparations
PT3954360T (pt) Preparação farmacêutica de hidratos de carbono para utilização terapêutica
GB201319437D0 (en) Delivery of drugs
SG10201913433SA (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
PT2953617T (pt) Composições farmacêuticas que incorporam fármacos de baixa dose
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
PL2988782T3 (pl) Postacie dawkowania do podawania substancji czynnych drogą doustną
GB201307659D0 (en) Preparation of drug particles by micronisation
IL244316A0 (en) A new composition of a drug
GB201318635D0 (en) Preservative free pharmaceutical compositions for ophthalmic administration

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed